|
Top 5 by Drug Sales, 2002 |
|||
| Company |
Pharma. Revenue* ($ bn) |
Net Profit ($ bn) |
R&D ($ bn) |
|
|
|||
| Pfizer |
28.29 |
9.13 |
5.18 |
| GSK |
27.06 |
6.96 |
4.11 |
| Merck |
20.13 |
7.15 |
2.67 |
| AstraZeneca |
17.84 |
2.84 |
3.07 |
| Johnson & Johnson |
17.15 |
6.6 |
3.96 |
|
*Most firms have income from other products as well; so total income exceeds pharmaceutical income | |||
Scheffler and Pathania Globalization and Health 2005 1:10 doi:10.1186/1744-8603-1-10 |
|||